A Pivotal Phase III Study to Evaluate Overall Survival Using MABp1 as a Monotherapy in Metastatic Colorectal Cancer Patients With Cachexia
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
The difference in median overall survival will be compared between the two arms.
baseline to 18 months
Aminah Jatoi, M.D.
United States: Food and Drug Administration
|Mayo Clinic Cancer Center||Rochester, Minnesota 55905|
|Montefiore Medical Center||Bronx, New York 10467-2490|
|Moores UCSD Cancer Center||La Jolla, California 92093-0658|
|Mid Dakota Clinic||Bismarck, North Dakota 58501|
|Karmanos Cancer Institute||Detroit, Michigan 48201|
|Lewis Hall Singletary Oncology Center||Thomasville, Georgia 31792|
|Innovative Clinical Research Institute||Downey, California 90241|
|UT Medical Center Cancer Institute||Knoxville, Tennessee 37920|